Table 3.
IHC markers for sensitivity to other agents, in recurrent and metastatic cases analyzed in this study.
| IHC MARKER | NUMBER POSITIVE | NUMBER INFORMATIVE | PERCENT | P-VALUE COMPARED TO CASES WITH PRIMARY ONLY | SIGNIFICANCE |
|---|---|---|---|---|---|
| TOPO1 | 35 | 61 | 57% | 0.009 | Sensitivity to irinotecan45 |
| SPARC | 42 | 79 | 53% | 0.13 | Sensitivity to nab-paclitaxel46,47 |
| PDGFR or cKIT* | 3 5 |
36 46 |
8% 11% |
0.018 | Sensitivity to multitargeted kinase inhibitors (imatinib, sunitinib)48 |
| AR | 8 | 74 | 11% | 0.15 | Sensitivity to androgen deprivation (Flutamide, leuprolide)49 |
| PR | 50 | 73 | 68% | 0.17 | Sensitivity to aromatase inhibitors (anastrozole)50,51 |
| ER | 2 | 74 | 3% | 1.0 | Sensitivity to aromatase inhibitors, (anastrozole) or antiestrogens (tamoxifen)51 |
Notes: P-value determined using Fisher’s exact test. The number positive indicates the number of cases where the protein expression was above the defined threshold. The number informative is the total number of cases in which a valid result was obtained.
*
Notably, the only cKIT mutation identified in the cohort was in a recurrent case.
Abbreviations: TOPO1, topoisomerase 1; SPARC, secreted protein acidic rich in cysteine; PR, progesterone receptor; ER, estrogen receptor; PDGFR, platelet-derived growth factor receptor; AR, androgen receptor.